Investor Relations

Polaris Group (the “Company” or “Polaris”) was incorporated in the British Cayman Islands on February 9, 2006 with a par value of NT$10 per share. The Company and its subsidiaries include Polaris Pharmaceuticals, Inc.,  DesigneRx Europe Limited, Polaris Pharmaceuticals Australia Pty Ltd., Polaris Pharmaceuticals Ireland Limited, Polaris Pharmaceuticals (Taiwan), Inc., DesigneRx Pharmaceuticals, Inc., Polaris Biopharmaceuticals, Inc., TDW HK Limited, DesigneRx Pharmaceuticals (Shanghai) Inc. and DesigneRx Pharmaceuticals (Chengdu) Inc., Lin Yang Biopharm, Ltd. and Genovior Biotech Corporation. The Group’s principal business activities are the manufacture and sale of new drugs, biotechnology services and drug testing. The Group’s core research is the novel cancer target drug ADI-PEG 20, which is currently undergoing human clinical trials for various cancers worldwide.


Scroll to Top
This site is registered on as a development site.